Erlamide 60mg Tablet

Like other anticancer medicines, Erlamide 60mg Tablet has mild to severe side effects. These are undesired symptoms observed in the body after taking this tablet. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention, but if you observe them continually, talk to your medical expert. Some of them are listed below:

Mild side effects:
Fatigue
Diarrhea
Hot flushes
Vomiting & Nausea
Joint and muscle pain
Skin rashes and itching
Tiredness and dizziness
Weight loss and loss of appetite
High blood pressure and sugar level

Severe Side effects:
Seizures
Leukopenia
Fractures in bones
Swelling in hand and feet
Increase in cholesterol level

Erlamide 60mg Tablet is a prescription-based anticancer drug that should be administered orally. It is advised to take this tablet after consulting your healthcare expert.

Erlamide 60mg Tablet belongs to the class of selective androgen receptor (AR) inhibitor that binds to the androgen receptor binding domain. The growth of prostate cancer relies on the sex hormone androgen. Cancer becomes resistant to standard hormonal therapies, due to which androgen receptor binds continuously to promote cancer growth. Erlamide 60mg Tablet blocks the signaling pathway, DNA binding, protein transportation in the nucleus, and AR-mediated transcription, which leads to the replication of the cancer cells. Erlamide 60mg Tablet blocks receptor activation and suppresses them from binding to androgen. In that way, it slows down the growth of the cancer cells.

It is advised not to miss any scheduled dosage of Erlamide 60mg Tablet. In case you miss a dose, consult your doctor immediately.
Don't overdose to compensate for the missed one. Contact your doctor or any healthcare provider and seek medical attention immediately in such cases.

Erlamide 60mg Tablet is not recommended in patients with a history of seizures, any brain injury, or a recent stroke (within one year).

Inform your doctor if you have a history of cardiovascular problems before taking Erlamide 60mg Tablet.

Using Erlamide 60mg Tablet makes your skin sensitive and dry. Use high SPF sunscreen before exposing to direct sunlight.

Your healthcare provider will decide how much you take and how often you need Erlamide 60mg Tablet. You are advised to follow the prescription strictly.

Your healthcare expert must measure your blood sugar & pressure, potassium level, and liver function tests at regular intervals. Taking the Erlamide 60mg Tablet can cause fluctuations in their levels.

​Use reliable methods of birth control and contraceptive pills to delay pregnancy while under treatment with Erlamide 60mg Tablet. Discuss with your healthcare expert the risks and benefits of taking this medicine if you want to conceive in the future.

​It is recommended to inform your doctor if you are taking any prescribed and non-prescribed medications, nutritional or vitamin supplements, or herbal products. These drugs can interact with Erlamide 60mg Tablet and may result in some severe side effects.

Chung, B. H., Huang, J., Uemura, H., Choi, Y. D., Ye, Z. Q., Suzuki, H., & Uemura, H. (2023). Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial. Asian Journal of Andrology, 25(6), 653-661.
Koshkin, V. S., & Small, E. J. (2023). Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic Advances in Urology, 10(12), 445-454.
Saad, F., Small, E. J., Feng, F. Y., Graff, J. N., Olmos, D., Hadaschik, B. A., & Smith, M. R. (2025). Deep prostate-specific antigen response following addition of apalutamide to ongoing androgen deprivation therapy and long-term clinical benefit in SPARTAN. European Urology, 81(2), 184-192.
Small, E. J., Saad, F., Chowdhury, S., Hadaschik, B. A., Graff, J. N., Olmos, D., & SPARTAN investigators. (2024). SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).
T’jollyn, H., Ackaert, O., Chien, C., Lopez-Gitlitz, A., McCarthy, S., Ruixo, C. P., & Agarwal, N. (2022). Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. Cancer Chemotherapy and Pharmacology, 89(5), 629-641.
Yue, W., Li, C., Wang, T., You, J., Sun, J., Liu, J., & Padanilam, B. J. (2025). Circadian rhythm-related miR-6883-5p suppresses enzalutamide-resistant prostate cancer. Non-coding RNA Research.